April 26 (Reuters) – British drugmaker AstraZeneca Plc
said on Tuesday Ironwood Pharmaceuticals Inc
would buy the U.S. marketing rights for its newly approved gout
drug for up to $265 million.
The post UPDATE 1-AstraZeneca sells U.S. gout drug rights to Ironwood for up to $265 mln appeared first on NASDAQ.